Study guide

4.2 Post-Exposure Management Protocols

Certification in Infection Prevention and Control CIC®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

0.1 About the CBIC CIC Exam & Certification Path 0.2 Exam Format, Domain Weighting & Study Strategy

2 Chapter 1: Identification of Infectious Disease Processes

1.1 Microorganisms & Microbial Pathogenesis 1.2 Diagnostic Microbiology & Laboratory Testing Methods 1.3 Infection Types & Clinical Syndromes 1.4 Antibiotic Resistance & Antimicrobial Stewardship Principles 1.5 Host Immunity, Defenses & Susceptibility Factors

3 Chapter 2: Surveillance and Epidemiologic Investigation

2.1 Surveillance System Design, Objectives & Case Definitions 2.2 Standardized NHSN Criteria for Healthcare-Associated Infections 2.3 Outbreak Investigation Methodology 2.4 Epidemiological Measures & Rates 2.5 Data Collection, Presentation, Visualization & Statistical Analysis

4 Chapter 3: Preventing and Controlling Transmission of Infectious Agents

3.1 Chain of Infection & Transmission Dynamics 3.2 Standard Precautions & Hand Hygiene Guidelines 3.3 Transmission-Based Precautions & Facility Isolation 3.4 Management of Multidrug-Resistant Organisms & High-Consequence Pathogens 3.5 Targeted Interventions & Evidence-Based Care Bundles

5 Chapter 4: Employee and Occupational Health

4.1 Healthcare Personnel Immunizations & Screening Programs 4.2 Post-Exposure Management Protocols 4.3 Occupational Safety, Work Restrictions & Fitness-for-Duty Evaluations

6 Chapter 5: Management, Leadership, and Communication

5.1 Infection Prevention Program Administration & Fiscal Impact 5.2 Infection Control Risk Assessment & Hazard Vulnerability Analysis 5.3 Policy Development, Regulatory Compliance & Public Health Reporting

7 Chapter 6: Education and Research Principles

6.1 Adult Education Principles & In-Service Training Design 6.2 Behavioral Change Models & Quality Improvement Methodology 6.3 Research Study Methodology, Literature Evaluation & Biostatistics

8 Chapter 7: Environment of Care

7.1 Environmental Surface Cleaning & Disinfection Controls 7.2 Healthcare Water Systems & Legionella Risk Management 7.3 Air Quality Controls, HVAC Systems & Construction ICRA 7.4 Regulated Medical Waste & Biohazard Disposal

9 Chapter 8: Cleaning, Sterilization, Disinfection, and Asepsis

8.1 Spaulding Classification System & Processing Workflow 8.2 Disinfection Levels & High-Level Disinfection (HLD) Monitoring 8.3 Sterilization Modalities, Chemical/Biological Indicators & Storage

4.2 Post-Exposure Management Protocols

Key Takeaways Explain This Topic AI

Immediate post-exposure management for bloodborne pathogen exposure requires washing needle sticks and wounds with soap and water and flushing mucous membranes with water or saline for 15 minutes.

HIV post-exposure prophylaxis (PEP) consists of a 3-drug antiretroviral regimen that should be initiated as soon as possible, ideally within 2 hours of exposure, and continued for 28 days.

Hepatitis B post-exposure prophylaxis depends on source HBsAg status and employee vaccine response; unvaccinated or non-responder employees exposed to HBsAg-positive blood require HBIG and HBV vaccination.

Routine PEP is not recommended for Hepatitis C exposures; management relies on baseline testing and follow-up HCV RNA testing at 3–6 weeks, with direct-acting antivirals initiated if infection develops.

Non-bloodborne post-exposure management includes macrolide prophylaxis for pertussis, post-exposure MMR/varicella vaccination or immune globulin for measles/varicella, and two-step post-exposure testing for tuberculosis.

Last updated: July 2026

Post-Exposure Management Protocols

Occupational exposures to bloodborne pathogens (BBP) and communicable infectious diseases represent high-priority medical emergencies in healthcare facilities. Infection preventionists, occupational health providers, and clinical supervisors must execute immediate, standardized management protocols to minimize transmission risks following an exposure.

Exposure Definition & Immediate First Aid

An occupational exposure is defined as a percutaneous injury (e.g., needlestick or cut with a contaminated sharp instrument), contact of mucous membranes (eyes, nose, mouth), or contact of non-intact skin (dermatitis, chapped, abraded skin) with blood, tissue, or potentially infectious body fluids.

Infectious vs. Non-Infectious Body Fluids

Potentially Infectious for BBP: Blood, semen, vaginal secretions, cerebrospinal fluid (CSF), synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, and amniotic fluid.

Non-Infectious for BBP (unless visibly bloody): Tears, sweat, urine, feces, saliva, vomitus, and nasal secretions.

Immediate First Aid Measures

Percutaneous Injuries & Skin Cuts: Wash the wound thoroughly with soap and water immediately. Do NOT squeeze or milk the wound , and do NOT apply harsh caustic antiseptics (such as bleach or concentrated iodine) into the wound.

Mucous Membrane Splashes: Flush the affected eyes, nose, or mouth with copious amounts of clean water or sterile saline for at least 15 minutes .

Reporting: Report the exposure incident immediately to occupational health or the emergency department supervisor.

Source Patient Evaluation

Immediate efforts must be made to identify and evaluate the source patient:

Obtain informed consent (per state law) and rapidly test source patient blood for:

HIV: 4th-generation HIV antigen/antibody immunoassay.

Hepatitis B: Hepatitis B surface antigen (HBsAg).

Hepatitis C: Hepatitis C virus antibody (anti-HCV) with reflex HCV RNA.

Critical Clinical Rule: Post-exposure prophylaxis (PEP) for the exposed employee must never be delayed while awaiting laboratory results from the source patient.

  • Bloodborne Pathogen PEP Algorithms
  • 1. Human Immunodeficiency Virus (HIV) PEP

Indications: Significant percutaneous or mucous membrane exposure to blood or infectious fluids from a known HIV-positive source or a high-risk unknown source.

Standard 3-Drug PEP Regimen: Preferred combination includes 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI):

Tenofovir disoproxil fumarate (TDF) 300 mg 300 \text{ mg} 300 mg + Emtricitabine (FTC) 200 mg 200 \text{ mg} 200 mg once daily, PLUS

Raltegravir 400 mg 400 \text{ mg} 400 mg twice daily OR Dolutegravir 50 mg 50 \text{ mg} 50 mg once daily.

Timing & Duration: PEP must be initiated as soon as possible, ideally within 2 hours post-exposure. Efficacy drops significantly if delayed beyond 72 hours. Total duration of treatment is 28 days .

Follow-up Testing Schedule: Baseline HIV testing, followed by repeat testing at 6 weeks and 4 months post-exposure (or 12 weeks post-exposure if using a 4th-generation Ag/Ab combination assay).

2. Hepatitis B Virus (HBV) PEP Protocol

Post-exposure management for HBV depends on the source patient's HBsAg status and the exposed employee's vaccination and anti-HBs response status:

Exposed Employee Status Source HBsAg Positive Source HBsAg Negative Source Unknown / Untested

Vaccinated Responder (anti-HBs ≥ 10 mIU/mL \ge 10 \text{ mIU/mL} ≥ 10 mIU/mL ) No treatment required No treatment required No treatment required

Vaccinated Non-Responder (anti-HBs < 10 mIU/mL < 10 \text{ mIU/mL} < 10 mIU/mL after 2 series) Administer 2 doses HBIG (1 mo apart) OR 1 dose HBIG + re-vaccination No treatment required Treat as if source is positive if high-risk source

Unvaccinated / Incomplete Series Administer 1 dose HBIG ( 0.06 mL/kg 0.06 \text{ mL/kg} 0.06 mL/kg ) immediately + initiate HBV vaccine series Complete HBV vaccine series Complete HBV vaccine series

Vaccinated, Unknown Response Test anti-HBs immediately. If ≥ 10 \ge 10 ≥ 10 , no PEP. If < 10 <10 < 10 , give 1 dose HBIG + vaccine booster No treatment required Test anti-HBs. If < 10 <10 < 10 , administer vaccine booster

Note: HBIG should be administered as soon as possible, ideally within 24 hours post-exposure (maximum window: 7 days).

3. Hepatitis C Virus (HCV) Management Protocol

PEP Recommendation: No post-exposure prophylaxis is recommended for HCV exposure. Neither immune globulin nor direct-acting antiviral (DAA) medications are approved for immediate post-exposure prophylaxis.

Baseline & Follow-up Testing:

Baseline testing of exposed employee: anti-HCV antibody, HCV RNA, and baseline ALT.

Early detection monitoring: Perform HCV RNA testing at 3 to 6 weeks post-exposure.

Confirmation testing: Perform anti-HCV testing at 4 to 6 months post-exposure (with reflex HCV RNA if positive).

Treatment Protocol: If acute HCV infection is confirmed (positive HCV RNA), refer the employee to a specialist for Direct-Acting Antiviral (DAA) therapy . DAA therapy yields cure rates (sustained virologic response) > 95 % > 95\% > 95% .

Non-Bloodborne Pathogen Post-Exposure Protocols

Occupational health must manage exposures to airborne, droplet, and contact pathogens effectively:

Pathogen / Disease PEP / Prophylactic Intervention Timing of Intervention Work Restriction Window

Tuberculosis (TB) Baseline IGRA/TST; repeat IGRA/TST at 8–10 weeks post-exposure Baseline immediately; repeat at 8–10 wk No restriction unless active TB disease suspected

Varicella (VZV) Varicella vaccine (healthy non-immune) or VARIZIG (high-risk/pregnant) Vaccine within 3–5 days; VARIZIG within 96 hr (up to 10 days) Exclude non-immune HCP from day 8 to day 21 post-exposure

Measles (Rubeola) MMR vaccine (non-immune) Administer within 72 hours post-exposure Exclude non-immune HCP from day 5 to day 21 post-exposure

Pertussis Oral Azithromycin ( 500 mg 500 \text{ mg} 500 mg day 1, 250 mg 250 \text{ mg} 250 mg days 2–5) regardless of Tdap status Initiate as soon as exposure identified Restrict symptomatic HCP until 5 days of antibiotics completed

Scabies Topical Permethrin 5% cream applied neck down overnight Apply single treatment immediately Restrict from care until 24 hours after treatment applied